On ECHEMI
Home > Drugs > Jiangsu Morning Brand Pharmaceutical Group Co., Ltd.
Jiangsu Morning Brand Pharmaceutical Group Co., Ltd.
  • Founded in:

    1996-05-28
  • Country:

    China China
  • Address:

    No. 666, Beijing East Road, Haimen District, Nantong City, Jiangsu Province
  • Tax NO.:

    913206001388073171
  • Registered Funds:

    55 million yuan
  • Website:

  • Email:

Related Drugs
Vitamin B4 tablets
The main ingredient of this product is vitamin B4, whose chemical name is adenine phosphate.
Name Description Content CAS NO. Registered Holders
Adenine phosphate salt(1:1)

This product is a drug for increasing white blood cells. Vitamin B4 is a component of nucleic acid and participates in the synthesis of RNA and DNA in the body. When white blood cells are deficient, it can promote white blood cell proliferation.

More

This product is a drug for increasing white blood cells. Vitamin B4 is a component of nucleic acid and participates in the synthesis of RNA and DNA in the body. When white blood cells are deficient, it can promote white blood cell proliferation.

70700-30-0 3
Ribavirin Tablets
Ribavirin
Name Description Content CAS NO. Registered Holders
Ribavirin

Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

More

Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

36791-04-5 33
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.